Vesneo (latanoprostene bunod) filed with FDA for glaucoma or ocular hypertension- Bausch + Lomb
Bausch + Lomb has submitted a New Drug Application (NDA) to the FDA seeking approval for Vesneo (latanoprostene bunod ophthalmic solution 0.024%), an IOP lowering single-agent eye drop dosed once daily, for patients with open angle glaucoma or ocular hypertension. The data submitted in the NDA support VESNEO as the first nitric-oxide donating agent for ophthalmic use.
Positive top-line results from the pivotal Phase III studies conducted with Vesneo (latanoprostene bunod; previously known as BOL-303259-X and NCX 116) for the reduction of intraocular pressure (IOP) in patients with Glaucoma or Ocular Hypertension were announced in 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins